Tanios Bekaii-Saab, MD, FACP

This Clinical Research Update expands on the earlier oral abstract presentation by Dr. Bekaii-Saab, and features an investigator-led discussion of both the significance of the research findings and the practice-changing potential of the data.

Tanios Bekaii-Saab , MD, FACP;

Eric Van Cutsem , MD, PhD;

07/10/2018

Molecular Unraveling in Bile Duct Cancer: What to Look For?

Tanios Bekaii-Saab , MD, FACP;

06/30/2021

Outcomes following FGFR inhibitor therapy in patients with cholangiocarcinoma: Multi-center single institution cohort experience

Background Cholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary system. Significant sequencing efforts have provided further insights o...

Tanios Bekaii-Saab , MD, FACP;

Jennifer J. Gile ;

Vanessa Wookey ;

Tyler Zemla ;

Qian Shi ;

Nguyen Tran ;

Amit Mahipal ;

06/27/2022

An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma

BackgroundColorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer-related mortality worldwide. PD-1/PD-L1 inhibition, in combination w...

Elena Elez Sr., MD, PhD;

C. Smolenschi ;

Dale Shepard ;

Tanios Bekaii-Saab , MD, FACP;

Jaroslaw Jac ;

06/25/2023

Debate: Are We Ready for Targeted Agents in First-Line Treatment of Advanced Biliary Tract Cancer Patients? - YES

Tanios Bekaii-Saab , MD, FACP;

07/06/2023